Recommandations for the registration of drugs used in the treatment of osteoarthritis : an update on biochemical markers; ; et al in Osteoarthritis and Cartilage (2001), 9 Detailed reference viewed: 7 (2 ULg) WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis; Reginster, Jean-Yves ; et alin Rheumatology (2001), 40(6), 699-702 Severe adult rheumatoid arthritis is a cause of progressive disability and increased mortality across Europe. A cure for the disease remains elusive, but control of symptoms and maintenance of individual ... [more ▼] Severe adult rheumatoid arthritis is a cause of progressive disability and increased mortality across Europe. A cure for the disease remains elusive, but control of symptoms and maintenance of individual independence is possible. Anti-cytokine therapies offer a new approach to disease management. They are effective after the failure of full doses of methotrexate, and are at least as effective as methotrexate in retarding the progression of radiological changes. Until more is known about the long-term safety and efficacy of these drugs they should be reserved for patients with severe disease who are progressing despite adequate doses of methotrexate or other disease-modifying anti-rheumatic drugs. They should be continued until therapeutic failure or intolerance. A comprehensive health economic evaluation is needed to optimally direct the use of these drugs. This should be undertaken when long-term safety and efficacy studies are completed. [less ▲] Detailed reference viewed: 8 (0 ULg) Recommendations for the registration of drugs used in the treatment of rheumatoid arthritis; ; et al in British Journal of Rheumatology (1998), 37 Detailed reference viewed: 5 (1 ULg) Recommendations for registration of drugs used in the treatment of osteoarthritis; ; et al in Annals of the Rheumatic Diseases (1996), 55 Detailed reference viewed: 4 (1 ULg) |
||